IDH1 and type 2 diabetes mellitus: IDH1 primarily exerts metabolic effects in vivo, IDH1 ectopic expression suppresses the production of brown adipocytes as a novel therapeutic target against obesity and related metabolic diseases such as type II diabetes and may represent a therapeutic target for the treatment of metabolic diseases (25).